Medrol and Peripheral embolism - a phase IV clinical study of FDA data

Summary:

Peripheral embolism is reported as a side effect among people who take Medrol (methylprednisolone), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Lasix, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Peripheral embolism when taking Medrol. It is created by eHealthMe based on reports of 23,951 people who have side effects when taking Medrol from the FDA, and is updated regularly.

What is Medrol?

Medrol has active ingredients of methylprednisolone. It is often used in rheumatoid arthritis. eHealthMe is studying from 24,443 Medrol users. Check the latest studies of Medrol.

What is Peripheral embolism?

Peripheral embolism (sudden interruption of blood flow to an organ or body part) is found to be associated with 238 drugs and 351 conditions by eHealthMe. Check the latest studies of Peripheral embolism.

On Jul, 10, 2026

23,951 people reported to have side effects when taking Medrol.
Among them, 29 people (0.12%) have Peripheral embolism.

Among these 29 people:

How long have people been on Medrol when they have Peripheral embolism? *

What is the gender of people who have Peripheral embolism when taking Medrol? *

female: 13.79 %
male: 86.21 %

What is the age of people who have Peripheral embolism when taking Medrol? *

What are other drugs people take besides Medrol? *

What are other side effects people have besides Peripheral embolism? *

Acute Kidney Failure: 23 people, 79.31%
Diarrhea: 23 people, 79.31%
Sinus Tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node): 20 people, 68.97%
Dyspnea (difficult or laboured breathing): 20 people, 68.97%
Infection: 20 people, 68.97%
Injury: 20 people, 68.97%
Tachyarrhythmia (disturbance of the heart rhythm in which the heart rate is abnormally increased): 20 people, 68.97%
Emotional Distress: 20 people, 68.97%
Oedema Peripheral (superficial swelling): 20 people, 68.97%
Fever: 20 people, 68.97%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 19 people, 65.52%
Neoplasm Malignant (cancer tumour): 2 people, 6.90%
Vaginal Bleeding Between Periods: 1 person, 3.45%
Sleep Disorder: 1 person, 3.45%
Pyogenic Liver Abscess (liver abscess caused by bacteria): 1 person, 3.45%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 3.45%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 3.45%
Birth Control: 1 person, 3.45%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Medrol and have Peripheral embolism?

- Check whether Peripheral embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Medrol:

Medrol (24,443 reports)

Browse all side effects of Medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral embolism:

Peripheral embolism (238 drugs)

Browse all the conditions that are associated with Peripheral embolism:

Peripheral embolism (351 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone (the active ingredients of Medrol) and Medrol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.